Company intelligence
As of September 24, 2026, BigHat Biosciences has raised at least $75M in equity across 1 sourced funding round.
BigHat Biosciences is a clinical-stage biotechnology company in San Mateo, California, that designs protein therapeutics using AI combined with automated lab experiments.[1] Its platform pairs machine-learning models with high-throughput experimentation that generates biological data to train and test those models.[1] Its lead program, BHB810, is a CDH17-directed antibody-drug conjugate for gastric cancer and other gastrointestinal tumors, and the first patient has been dosed in a Phase 1 trial.[1] A second candidate, BHB299, is a T-cell engager targeting CEACAM6-expressing solid tumors, and BigHat plans to start human trials of it in 2027.[1] BigHat has collaborations with Amgen, Merck, Johnson & Johnson, AbbVie and Lilly.[1] Stefan Weigand, former head of large molecule research at Roche, became chief scientific officer in June 2026.[1] The money will fund its data-generation platform and move BHB810 and BHB299 toward clinical readouts.[1]
The company lists more than 85 employees.[2]
BigHat Biosciences is a San Mateo, California, clinical-stage AI antibody company that raised a $75 million Series C in September 2026.
BigHat Biosciences is a clinical-stage, AI-driven protein therapeutics company based in San Mateo, California. The company develops antibody therapeutics and lists a current focus on oncology, inflammatory disease and immunology. Its About page reports more than 85 employees and $223 million in funding.[1],[2],[3]
BigHat Biosciences calls its lab and platform Milliner, and describes three layers. Milliner is an automated wet lab built around cell-free protein synthesis. Reccy is a laboratory data system that collects instrument output into labeled training data. RADS is the production machine-learning layer that trains models on BigHat's own data.[4]
BigHat Biosciences was founded in 2019. Peyton Greenside, the company's CEO, wrote in a company post that Greenside and a co-founder named Mark started it to combine machine learning and synthetic biology for therapeutic antibody design.[5]
BigHat Biosciences changed CEOs in early 2025. In a post dated March 4, 2025, Greenside wrote about stepping into the CEO role and thanked Mark for serving as BigHat's first CEO. A December 2023 AbbVie press release names the CEO of BigHat at that time as Mark DePristo.[5],[6]
BigHat Biosciences signed a Lilly collaboration on April 17, 2025, closed a $44 million Series B extension during 2025, and announced completion of its J&J collaboration on October 28, 2025. The company also licensed Synaffix antibody-drug conjugate technology in October 2024.[7],[1],[8],[9]
BigHat Biosciences announced a $75 million Series C on September 24, 2026, bringing total funding raised to $223 million. DFJ Growth and Premji Invest co-led the round.[1],[10]
BigHat Biosciences has not disclosed a valuation for the Series C or any earlier round. No revenue figure has been disclosed.[1],[10]
BigHat Biosciences lists nine leaders on its About page. They are Peyton Greenside, CEO and co-founder; Eddie Abrams, chief information officer; John Corbin, chief development officer; Liz Schwarzbach, chief business officer; Stefan Weigand, chief scientific officer; Charbel Eid, VP of platform; Hunter Elliott, VP of machine learning; Ryan Henrici, VP of discovery medicine; and Brett Weinstein, VP of finance.[2]
BigHat Biosciences appointed Stefan Weigand as chief scientific officer on June 10, 2026. The company's release says Weigand joined from Roche, where he was head of large molecule research overseeing a global team of approximately 350 scientists, and brings more than 25 years of drug discovery experience.[11]
BigHat Biosciences appointed John Corbin as chief development officer in June 2023. The Series C release describes Corbin as the former chief technology officer at Tizona Therapeutics.[1]
BigHat Biosciences signed a research collaboration with AbbVie on December 5, 2023, covering oncology and neuroscience antibodies. Under the terms, BigHat received an upfront payment of $30 million and may receive up to approximately $325 million in aggregate research and development milestones, plus further commercial milestones and tiered royalties.[6]
BigHat Biosciences expanded its Lilly relationship by joining Lilly TuneLab on January 7, 2026. On October 6, 2026 the company said Lilly had released NanoLab, a TuneLab VHH developability model built on data generated by BigHat's Milliner platform.[12],[13]
BigHat Biosciences announced on October 28, 2025 that it had completed a strategic collaboration with Johnson & Johnson, with the legal entity named as Janssen Biotech, Inc. The release says the next stage involves advancing multiple novel sequences for neuroscience medicines. The Series C release also reports three project collaborations with Merck and names Amgen as a collaborator.[8],[1]
BigHat Biosciences announced on October 30, 2024 that Synaffix, a Lonza company, had licensed its antibody-drug conjugate technology to BigHat for a new pipeline program. The announcement says Milliner was used to design the antibody that was paired with Synaffix's technologies.[9]
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2026 | Series C | $75M | — | WithCatalio Capital ManagementLG Technology Ventures8VCAndreessen HorowitzEli Lilly and CompanyMerck Global Health Innovation FundQuadrille CapitalGRIDS CapitalIntermountain VenturesSection 32Sigmas GroupAmgen VenturesAlexandria Venture InvestmentsDiscovery Ventures | BioSpace |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
The company raised an $80 million Series B in 2022.[1] It closed a $44 million Series B extension in 2025, led by pharmaceutical and strategic investors.[1] On September 24, 2026, BigHat announced a $75 million Series C, bringing its total funding to $223 million.[1] Existing investors in the round included 8VC, Andreessen Horowitz, Amgen Ventures, Eli Lilly and Company and Merck Global Health Innovation Fund.[1]
Island, Cyera and BigHat Biosciences alone raised more than $1.1 billion this week to build the layer that governs what AI agents can access and do -- evidence the market has already priced in the exact failure mode this issue's lead story just demonstrated.
BigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, taking total funding to $223 million as its AI-designed antibody-drug conjugate enters a Phase 1 trial for gastric cancer.
On September 24, 2026, BigHat announced a $75 million Series C, bringing its total funding to $223 million.[1]
BigHat Biosciences closed a $44 million Series B extension in 2025, led by pharmaceutical and strategic investors.[1]
Peyton Greenside is co-founder and CEO.[1]
BigHat Biosciences is a clinical-stage biotechnology company in San Mateo, California, that designs protein therapeutics using AI combined with automated lab experiments.[1]
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.